ReCode Therapeutics

At ReCode, we’re continually inspired by the Cystic Fibrosis Foundation’s impact and the progress made possible by their support. This collaboration has strengthened our science, helping us understand the challenges of CF on a deeper level and design solutions for the community. Together, we’re aiming to build a world where cystic fibrosis is met with more effective treatments.

In collaboration with Emily's Entourage, we’re pushing boundaries in cystic fibrosis (CF) research, especially for those with limited treatment options. Together, we’re building a future where the challenges of CF are met with hope and new possibilities for everyone with CF. Sign up for Emily's Entourage clinical trial connect to find a clinical trial that's right for you: https://lnkd.in/grgpT9Et Video courtesy of Emily's Entourage

Kate Cutler shares what it means to support her husband, Mel, in his cystic fibrosis (CF) journey—from managing treatments and medications to anticipating his needs as he gets older. For many in the CF community, caregiving isn’t just about responsibility—it’s about love, partnership, and protecting the person you love most. Watch to hear Kate’s perspective. Hear more CF Stories via the link below: https://lnkd.in/gVk-ikqV #CysticFibrosis #Caregiving #CFCommunity #ReCodeTherapeutics

This International Women’s Day, we celebrate the extraordinary women at ReCode and across the scientific community who are driving breakthroughs and transforming patient care. At ReCode, we are committed to creating opportunities for women in science to thrive. We support mentorship, invest in growth, and foster an environment where future leaders can push the boundaries of what’s possible. Today, we celebrate the women at ReCode and across the scientific community who are redefining the future of medicine. Their impact will inspire generations to come. #IWD #InternationalWomensDay #WomenInSTEM #Innovation #ReCodeTherapeutics

Today is Employee Appreciation Day, an opportunity for us to recognize the scientists, researchers, clinicians, and operational teams who support ReCode’s efforts to bring new genetic medicines to patients. Your dedication fuels discovery, advances our pipeline, and brings us closer to potential life-changing treatments for patients. We are committed to fostering an environment where every team member can grow, collaborate, and push the boundaries of what’s possible.? ? Thank you for your expertise, passion, and commitment to transforming patient care. Today, and every day, we appreciate you. ? #EmployeeAppreciationDay #TeamReCode #Innovation #ThankYou #EAD #ReCodeTherapeutics

As a caregiver, understanding the symptoms of cystic fibrosis can make a world of difference in managing your loved one’s health. Persistent cough, frequent infections, and wheezing are among the signs to watch for. ReCode’s clinical study of an inhaled mRNA therapy is focused on addressing CF symptoms at their source—providing potential new hope for families affected by CF. Find out how we’re tackling CF symptoms at their genetic roots with a new investigational mRNA therapy and clinical trial: https://lnkd.in/gaUibNTn #CysticFibrosis #CFResearch #mRNATherapy

ReCode’s clinical study for cystic fibrosis uses cutting-edge mRNA therapy to tackle CF at its genetic roots. This investigational approach leverages our Selective Organ Targeting (SORT) Lipid Nanoparticle (LNP) platform for targeted delivery to lung cells. Learn more about precision mRNA therapy in CF at https://recodetx.com/cf/

On Rare Disease Day, ReCode Therapeutics honors the strength, diversity, and pride of those affected by rare diseases. Our commitment to these communities is unwavering as we work to develop transformative genetic medicines. Join us in recognizing the resilience of patients and families, and in celebrating the power of research and innovation to change lives. #RareDiseaseDay #GeneticMedicine

At ReCode Therapeutics, we’re utilizing our SORT LNP platform to deliver inhaled mRNA directly to targeted cells in the lungs. Our approach doesn’t alter your existing genes; it adds a healthy copy to improve the way your body functions. This new approach aims to bring potential new treatment options to the 10% of the CF community that have genetic mutations that do not respond to current CFTR modulators. Learn more about the SORT LNP platform: https://recodetx.com/cf/ #cysticfibrosis #cf

Did you know that about 10% of people with cystic fibrosis have genetic changes that current treatments can’t address? These specific changes prevent the production of the CFTR protein, which is essential for current therapies to work. We’re working on an investigational therapy designed to help this subgroup of patients with CF. Learn more at https://lnkd.in/gaUibNTn